China Ramps Up Diagnostics Efforts To Deal With Diabetes Surge; Mandates Screening For At-risk Populations
This article was originally published in PharmAsia News
Executive Summary
China will enact regulations to mandate regular screening for diabetes among high-risk populations, which could spur a surge in demand for diabetes treatments and diagnostic devices that dwarfs that of the United States.
You may also be interested in...
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year
China At Ground Zero In Explosion of New Diabetes Cases; International Federation Now Projects 500 Million Diabetics Worldwide By 2030
BEIJING - A vast new study conducted by scientists in North America and Asia places China at ground zero in terms of an explosion in the incidence of diabetes, and "shows that the global burden of diabetes is far larger than previously estimated," according to a scholar at the Brussels, Belgium-based International Diabetes Federation
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.